Oscar Health Q4 2023 Earnings Report
Key Takeaways
Oscar Health announced strong Q4 and full-year 2023 results, with core metrics exceeding expectations. The company delivered on its commitment for Insurance Company Adjusted EBITDA profitability and anticipates consolidated Adjusted EBITDA profitability in 2024. They served over 1.3 million members and are focused on sustainable margin expansion.
Oscar Health reported strong 2023 results, exceeding expectations for the full year.
The company delivered on its commitment for Insurance Company Adjusted EBITDA profitability.
Oscar Health has a clear path to consolidated Adjusted EBITDA profitability in 2024.
Oscar Health served more than 1.3 million members in 2023.
Oscar Health
Oscar Health
Oscar Health Revenue by Segment
Forward Guidance
The Company anticipates Total Revenue of $8.3 billion to $8.4 billion, a Medical Loss Ratio of 80.2% to 81.2%, a SG&A Expense Ratio of 20.5% to 21.0%, and Total Company Adjusted EBITDA of $125 million to $175 million.
Positive Outlook
- Total Revenue of $8.3 billion to $8.4 billion
- Medical Loss Ratio of 80.2% to 81.2%
- SG&A Expense Ratio of 20.5% to 21.0%
- Total Company Adjusted EBITDA of $125 million to $175 million
- Clear line of sight into consolidated Adjusted EBITDA profitability in 2024
Challenges Ahead
- Actual results may differ materially depending on a number of factors.
- Uncertainty in estimating stock-based compensation expense.
- Dependence on various factors, some of which are outside of Oscar’s control.
- New factors emerge from time to time, and it is not possible for us to predict which will arise.
- Heightened competition in the markets in which we participate
Revenue & Expenses
Visualization of income flow from segment revenue to net income